ro13-9904 and Psoriasis

ro13-9904 has been researched along with Psoriasis* in 2 studies

Other Studies

2 other study(ies) available for ro13-9904 and Psoriasis

Article	Year
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab. International journal of dermatology, 2020, Volume: 59, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Brugada Syndrome; Ceftriaxone; Clinical Laboratory Techniques; Continuous Positive Airway Pressure; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Middle Aged; Nasopharynx; Pandemics; Pneumonia, Viral; Psoriasis; SARS-CoV-2; Treatment Outcome	2020
Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor. Infection, 2015, Volume: 43, Issue:6 A 57-year-old woman, receiving TNF-alpha inhibitor adalimumab for psoriasis, presented with early Lyme neuroborreliosis (Bannwarth's syndrome). Discontinuation of adalimumab and 14-day therapy with ceftriaxone resulted in a smooth course and favorable outcome of Lyme borreliosis. This is the first report on Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor. Topics: Adalimumab; Anti-Bacterial Agents; Ceftriaxone; Female; Humans; Immunologic Factors; Lyme Neuroborreliosis; Middle Aged; Psoriasis; Treatment Outcome	2015

Article

Year

Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.

International journal of dermatology, 2020, Volume: 59, Issue:8

Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Brugada Syndrome; Ceftriaxone; Clinical Laboratory Techniques; Continuous Positive Airway Pressure; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Middle Aged; Nasopharynx; Pandemics; Pneumonia, Viral; Psoriasis; SARS-CoV-2; Treatment Outcome

2020

Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.

Infection, 2015, Volume: 43, Issue:6

A 57-year-old woman, receiving TNF-alpha inhibitor adalimumab for psoriasis, presented with early Lyme neuroborreliosis (Bannwarth's syndrome). Discontinuation of adalimumab and 14-day therapy with ceftriaxone resulted in a smooth course and favorable outcome of Lyme borreliosis. This is the first report on Lyme neuroborreliosis in a patient treated with TNF-alpha inhibitor.

Topics: Adalimumab; Anti-Bacterial Agents; Ceftriaxone; Female; Humans; Immunologic Factors; Lyme Neuroborreliosis; Middle Aged; Psoriasis; Treatment Outcome

2015